# Takeda (TAK) Q2 FY2026 earnings

Results filed 2026-10-29 for the quarter ended 2026-09-30. Source page: https://earnings.opennash.com/companies/tak/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000345/0001395064-26-000345-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Takeda's growth leaned on subcutaneous ENTYVIO and immunoglobulin demand, while new launches grew 17.3% at constant exchange rates but remain a small share of the business.

Demand centered on gastroenterology and plasma-derived therapies. ENTYVIO grew with the subcutaneous formulation in the U.S. and Europe, and subcutaneous immunoglobulins CUVITRU and HYQVIA grew at double-digit rates. Newer products added momentum: LIVTENCITY, VONVENDI, ADZYNMA, FRUZAQLA and QDENGA each grew on launch or expanded-use gains. TRINTELLIX benefited from U.S. pricing and payer mix. Takeda also discontinued its cell therapy research.
Management is pushing late-stage pipeline programs, including arcotatug tavatecan (TAK-921), elritercept (TAK-226) and TAK-928, while a transformation program continues with restructuring costs. The main tension is that established brands were broadly flat and products losing exclusivity declined. New launches are only 4% of core revenue, so they must scale to replace what is fading.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue (six months ended Sept 30, 2026) | JPY 2,407.0 billion | up 8.4% at actual exchange rates, down 1.0% at constant exchange rates from a year ago | GAAP |
| Operating profit (six months) | JPY 406.7 billion | up 60.4% at actual exchange rates, up 45.0% at constant exchange rates | GAAP |
| Net profit attributable to owners (six months) | JPY 305.6 billion | up 171.8% at actual exchange rates, up 148.9% at constant exchange rates | GAAP |
| Diluted EPS (JPY, six months) | 189.52 | up from 70.45 a year ago | GAAP |
| Core EPS (six months) | JPY 308 | up 10.5% at actual exchange rates, down 1.2% at constant exchange rates | non-GAAP |
| Net cash from operating activities (six months) | JPY 431.9 billion | down JPY 161.8 billion from a year ago | GAAP |
| Core operating profit (six months) | JPY 710.6 billion | up 11.2% at actual exchange rates, up 0.7% at constant exchange rates | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Gastroenterology (GI) | JPY 776.8 billion | up 12.1% at actual exchange rates, up 2.5% at constant exchange rates |
| Rare Diseases | JPY 395.7 billion | up 4.0% at actual exchange rates, down 5.6% at constant exchange rates |
| Plasma-Derived Therapies (PDT) | JPY 561.2 billion | up 8.5% at actual exchange rates, down 1.5% at constant exchange rates |
| Oncology | JPY 317.0 billion | up 10.1% at actual exchange rates, up 0.9% at constant exchange rates |
| Vaccines | JPY 36.6 billion | up 15.7% at actual exchange rates, up 7.7% at constant exchange rates |
| Neuroscience | JPY 220.9 billion | up 7.2% at actual exchange rates, down 1.6% at constant exchange rates |
| ENTYVIO | JPY 541.7 billion | up 13.0% at actual exchange rates, up 2.7% at constant exchange rates |

## Key takeaways

1. **Subcutaneous ENTYVIO is extending the GI franchise** ENTYVIO growth in the U.S. was accompanied by growth of the subcutaneous formulation, and European growth was supported by increased subcutaneous use and rising patient numbers. This shows the franchise is being sustained through formulation, not only exchange rates.
2. **Subcutaneous immunoglobulins show strong global demand** CUVITRU and HYQVIA, both subcutaneous immunoglobulin therapies, posted double digit percentage sales growth on continued strong demand globally. Intravenous GAMMAGARD LIQUID/KIOVIG only slightly increased.
3. **New launches grow fast but remain small** New Launches grew by 17.3% at CER yet represented only 4% of Core Revenue. Core In-line Brands were 58% of Core Revenue and grew only 0.5% at CER.
4. **Rare disease and vaccine launches keep building** VONVENDI grew on its expanded indication enabling prophylactic use in adults, ADZYNMA grew post-launch in Europe, and QDENGA grew post-launch in Latin America. LIVTENCITY reflected strong U.S. market penetration.
5. **Pipeline spend shifts to late-stage programs** R&D rose on late-stage programs including arcotatug tavatecan (TAK-921), elritercept (TAK-226) and TAK-928. Takeda also impaired its gamma delta T-cell platform in the prior year after deciding to discontinue cell therapy research.

## Questions

**What is driving growth of Takeda's ENTYVIO?** Growth of the subcutaneous formulation in the U.S., and in Europe continued patient growth supported by increased subcutaneous use. Favorable exchange rates also helped reported sales.
**How are Takeda's newer products performing?** New Launches grew by 17.3% at constant exchange rates but made up only 4% of Core Revenue. Products such as LIVTENCITY, VONVENDI, ADZYNMA, FRUZAQLA and QDENGA all grew.
**Which late-stage pipeline programs is Takeda investing in?** R&D expenses rose on late-stage programs including arcotatug tavatecan (TAK-921), elritercept (TAK-226) and TAK-928.
**What is the main challenge facing Takeda's established portfolio?** Core In-line Brands were broadly flat, and growth from New Launches was more than offset by declines in loss of exclusivity-impacted and mature products. Excluding currency effects, Core Revenue slightly declined.
**What is happening with demand for Takeda's plasma-derived therapies?** Subcutaneous immunoglobulins CUVITRU and HYQVIA saw double digit sales growth on strong global demand. Albumin sales rose on exchange rates but fell in the U.S.

## Slides and investor documents

- [OPEN THE PDF   Arrow down](https://assets-dam.takeda.com/image/upload/v1793241392/Global/Investor/Financial-Results/FY2026/Q2/qr2026_q2_Pipeline_table_en.pdf) (Document)
- [OPEN THE PDF   Arrow down](https://assets-dam.takeda.com/image/upload/v1793242146/Global/Investor/Financial-Results/FY2026/Q2/qr2026_q2_Expected_timelines_en.pdf) (Document)

